High-Dose Inactivated Influenza Vaccine Quadrivalent for Older Adults

Abstract

Objective:

To review the efficacy and safety of the high-dose inactivated influenza vaccine quadrivalent (HD-IIV4) in the prevention of influenza in older adults.

Data Sources:

A literature search was performed using PubMed and Google Scholar with the search terms high-dose, influenza vaccine, and quadrivalent. Other resources included the Centers for Disease Control and Prevention (CDC), the prescribing information, and the manufacturer’s website.

Study Selection and Data Extraction:

All relevant English-language articles of studies assessing the efficacy and safety of HD-IIV4 were included.

Data Synthesis:

HD-IIV4 is licensed by the Food and Drug Administration for the prevention of influenza in adults aged 65 years and older. The safety and immunogenicity of HD-IIV4 was demonstrated in a phase 3 trial, and the efficacy of the trivalent formulation (HD-IIV3) was demonstrated in a phase 3b-4 trial. HD-IIV4 carries a warning regarding the occurrence of Guillain-Barré syndrome. Adverse reactions, including injection-site pain and myalgia, were reported more frequently with HD-IIV4 than with HD-IIV3.

Relevance to Patient Care and Clinical Practice:

Although the CDC recommends any age-appropriate influenza vaccine for adults aged 65 years and older, HD-IIV4 was associated with improved immunogenicity against the added B strain and HD-IIV3 provided better protection against influenza than the standard-dose vaccine. Other influenza vaccines have weaker evidence of efficacy in older adults. Therefore, HDIIV4 should be recommended as the vaccine of choice in adults aged 65 years and older.

Conclusion:

HD-IIV4 has proven immunogenic, safe, and effective in preventing influenza in older adults and should be recommended as the vaccine of choice in this patient population.

Keywords

aging formulary immunizations preventative medicine vaccines viral infections

Get full access to this article

View all access options for this article.

References

Centers for Disease Control and Prevention. Disease burden of influenza. Accessed April 10, 2020. https://www.cdc.gov/flu/about/burden/index.html?CDC_AA_refVal=https%3A%2F%2Fwww.cdc.gov%2Fflu%2Fabout%2Fdisease%2Fburden.htm

Centers for Disease Control and Prevention. People 65 years and older & influenza. Accessed April 10, 2020. https://www.cdc.gov/flu/highrisk/65over.htm

Grohskopf

Alyanak

Broder

Walter

Fry

Jernigan

DB.

Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices—United States, 2019-20 influenza season. MMWR Recomm Rep. 2019;68:1-21.

Office of Disease Prevention and Health Promotion. Immunization and infectious diseases. Accessed April 10, 2020. https://www.healthypeople.gov/2020/topics-objectives/topic/immunization-and-infectious-diseases/objectives

Centers for Disease Control and Prevention. CDC seasonal flu vaccine effectiveness studies. Accessed April 10, 2020. https://www.cdc.gov/flu/vaccines-work/effectiveness-studies.htm

Centers for Disease Control and Prevention. Immunogenicity, efficacy, and effectiveness of influenza vaccines. Accessed April 10, 2020. https://www.cdc.gov/flu/professionals/acip/immunogenicity.htm

Crooke

Ovsyannikova

Poland

Kennedy

RB.

Immunosenescence and human vaccine immune responses. Immun Ageing. 2019;16:25. doi:10.1186/s12979-019-0164-9

DiazGranados

Dunning

Kimmel

, et al. Efficacy of high-dose versus standard-dose influenza vaccine in older adults. N Engl J Med. 2014;371:635-645. doi:10.1056/NEJMoa1315727

Van Buynder

Konrad

Van Buynder

, et al. The comparative effectiveness of adjuvanted and unadjuvanted trivalent inactivated influenza vaccine (TIV) in the elderly. Vaccine. 2013;31:6122-6128. doi:10.1016/j.vaccine.2013.07.059

10.

Dunkle

Izikson

Patriarca

, et al. Efficacy of recombinant influenza vaccine in adults 50 years of age or older. N Engl J Med. 2017;376:2427-2436. doi:10.1056/NEJMoa1608862

11.

Fluzone® High-Dose Quadrivalent. Package insert. Sanofi Pasteur, Inc; 2019.

12.

Roguski

Fry

Travel-related infectious diseases—influenza. In: Centers for Disease Control and Prevention Yellow Book 2020: Health Information for International Travel. Oxford University Press; 2017:chap 4. https://wwwnc.cdc.gov/travel/yellowbook/2020/travel-related-infectious-diseases/influenza. Accessed April 10, 2020.

13.

Treanor

. Influenza (including avian influenza and swine influenza). In: Bennett

Dolin

Blaser

, eds. Mandell, Douglas, and Bennett’s Principles and Practice of Infectious Diseases. 9th ed. Elsevier; 2020:2143-2168.

14.

US Food and Drug Administration. 2020 Meeting materials, Vaccines and Related Biological Products Advisory Committee. Published March 4, 2020. Accessed April 10, 2020. https://www.fda.gov/advisory-committees/vaccines-and-related-biological-products-advisory-committee/2020-meeting-materials-vaccines-and-related-biological-products-advisory-committee

15.

Keitel

Cate

Atmar

, et al. Increasing doses of purified influenza virus hemagglutinin and subvirion vaccines enhance antibody responses in the elderly. Clin Diagn Lab Immunol. 1996;3:507-510.

16.

Falsey

Treanor

Tornieporth

Capellan

Gorse

GJ.

Randomized, double-blind controlled phase 3 trial comparing the immunogenicity of high-dose and standard-dose influenza vaccine in adults 65 years of age and older. J Infect Dis. 2009;200:172-180. doi:10.1086/599790

17.

Sanchez

Matsuoka

Inoue

, et al. Immunogenicity and safety of high-dose quadrivalent influenza vaccine in Japanese adults ≥65 years of age: a randomized controlled clinical trial. Hum Vaccin Immunother. 2020;16:858-866. doi:10.1080/21645515.2019.1677437

18.

Chang

Meng

Janosczyk

Landolfi

Talbot

; QHD00013 Study Group. Safety and immunogenicity of high-dose quadrivalent influenza vaccine in adults ≥65 years of age: a phase 3 randomized clinical trial. Vaccine. 2019;37:5825-5834. doi:10.1016/j.vaccine.2019.08.016.

19.

Shay

Chillarige

Kelman

, et al. Comparative effectiveness of high-dose versus standard-dose influenza vaccines among US Medicare beneficiaries in preventing postinfluenza deaths during 2012-2013 and 2013-2014. J Infect Dis. 2017;215:510-517. doi:10.1093/infdis/jiw641

20.

Young-Xu

Van Aalst

Mahmud

, et al. Relative vaccine effectiveness of high-dose versus standard-dose influenza vaccines among Veterans Health Administration patients. J Infect Dis. 2018;217:1718-1727. doi:10.1093/infdis/jiy088

21.

Robison

Thomas

AR.

Assessing the effectiveness of high-dose influenza vaccine in preventing hospitalization among seniors, and observations on the limitations of effectiveness study design. Vaccine. 2018;36:6683-6687. doi:10.1016/j.vaccine.2018.09.050

22.

Young-Xu

Snider

van Aalst

, et al. Analysis of relative effectiveness of high-dose versus standard-dose influenza vaccines using an instrumental variable method. Vaccine. 2019;37:1484-1490. doi:10.1016/j.vaccine.2019.01.063

23.

van Aalst

Gravenstein

Mor

, et al. Comparative effectiveness of high dose versus adjuvanted influenza: a retrospective cohort study. Vaccine. 2020;38:372-379. doi:10.1016/j.vaccine.2019.09.105

24.

Centers for Disease Control and Prevention. Vaccine information statement: influenza (flu) vaccine (inactivated or recombinant): what you need to know. Accessed April 15, 2020. https://www.cdc.gov/vaccines/hcp/vis/vis-statements/flu.pdf

25.

Department of Health and Human Services. Vaccine adverse event reporting system. Accessed April 10, 2020. https://vaers.hhs.gov/

26.

Sanofi Pasteur Inc. Fluzone high-dose quadrivalent. Accessed April 10, 2020. https://sanofiflu.com/fluzone-high-dose-influenza-vaccine.html

27.

Seqirus. Fluad quadrivalent. Accessed April 10, 2020. https://flu.seqirus.com/FluadCategory/Fluad/p/FluadPre?seasonCategoryCode=Seqirus_PreSeason

28.

Dougherty

Chahine

EB.

Providing additional “muscle” for older adults through optimal influenza vaccine selection. Ann Pharmacother. 2018;52:936-941. doi:10.1177/1060028018772579

29.

Dooling

Guo

Patel

, et al. Recommendations of the Advisory Committee on Immunization Practices for use of herpes zoster vaccines. MMWR Morb Mortal Wkly Rep. 2018;67:103-108. doi:10.15585/mmwr.mm6703a5

30.

Schillie

Harris

Link-Gelles

Romero

Ward

Nelson

Recommendations of the Advisory Committee on Immunization Practices for use of a hepatitis B vaccine with a novel adjuvant. MMWR Morb Mortal Wkly Rep. 2018;67:455-458. doi:10.15585/mmwr.mm6715a5

31.

Red Book [online]. Fluzone high-dose 2019-20 formula. Accessed April 10, 2020.

32.

Becker

Chit

DiazGranados

Maschio

Yau

Drummond

High-dose inactivated influenza vaccine is associated with cost savings and better outcomes compared to standard-dose inactivated influenza vaccine in Canadian seniors. Hum Vaccin Immunother. 2016;12:3036-3042. doi:10.1080/21645515.2016.1215395

33.

van Aalst

Russo

Neupane

, et al. Economic assessment of a high-dose versus a standard-dose influenza vaccine in the US Veteran population: estimating the impact on hospitalization cost for cardio-respiratory disease. Vaccine. 2019;37:4499-4503. doi:10.1016/j.vaccine.2019.06.066

34.

Shireman

Ogarek

Gozalo

, et al. Cost benefit of high-dose vs standard-dose influenza vaccine in a long-term care population during an A/H1N1-predominant influenza season. J Am Med Dir Assoc. 2019;20:874-878. doi:10.1016/j.jamda.2018.12.003